WALD WALDENCAST ACQUISITION CORP

Waldencast plc Names Philippe Gautier Chief Financial Officer and Chief Operating Officer

Waldencast plc Names Philippe Gautier Chief Financial Officer and Chief Operating Officer

NEW YORK, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Waldencast plc, (NASDAQ: WALD) (“Waldencast” or “the Company”), a global multi-brand beauty and wellness platform, today announced that Philippe Gautier will join the Company as Chief Financial Officer and Chief Operating Officer on October 19, 2022. In this role, Mr. Gautier will also serve as the principal financial officer of the Company.

Mr. Gautier comes to Waldencast following a successful, thirty-year career leading the finance and operations areas of prestigious global consumer companies. Most recently, Mr. Gautier served as Group Chief Financial Officer at Selecta – a KKR portfolio company. Prior to this, he spent five years as Group Chief Financial Officer and Operations, for SMCP (Sandro, Maje, Claudie Pierlot, De Fursac). In addition, for more than a decade, Mr. Gautier served as Chief Financial Officer of major brands at Kering, including Sergio Rossi and Puma, working in Italy and in the United States. Mr. Gautier began his career at HSBC asset management in Tokyo.

Michel Brousset, Waldencast’s Founder and CEO states, “We are pleased to attract Philippe to Waldencast and believe his vast financial and operational experience, business acumen and proven track record of delivering financial improvement and operational excellence while acquiring, integrating, nurturing, and developing global luxury consumer brands will be highly valuable to us as we position Waldencast to achieve its ambition to build out a world class portfolio of beauty and wellness brands.”

“I am thrilled to join Waldencast and bring my experience to elevate the solid foundation that has been created to advance the company’s ambition to build a global best-in-class beauty and wellness multi-brand platform,” said Mr. Gautier. “I look forward to working with the Waldencast team and contributing to the success of this incredible growth company for many years into the future.”

About Waldencast

Founded by Michel Brousset and Hind Sebti, Waldencast’s ambition is to build a global best-in-class beauty and wellness operating platform by developing, acquiring, accelerating, and scaling conscious, high-growth, purpose-driven brands.  Waldencast’s vision is fundamentally underpinned by its brand-led business model that ensures proximity to its customers, business agility and market responsiveness, while maintaining each brand’s distinct DNA. The first step in realizing its vision was the business combination with Obagi Skincare and Milk Makeup. As part of the Waldencast platform, brands will benefit from the operational scale of a multi-brand platform, expertise in managing global beauty brands at scale, a balanced portfolio to mitigate category fluctuations, asset-light efficiency and the market responsiveness and speed of entrepreneurial indie brands. For more information please visit: .

Contacts:

Investors

ICR

Allison Malkin/Annie Erner/Nina Weiss

Media

ICR

Brittney Fraser/Alecia Pulman



EN
27/09/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on WALDENCAST ACQUISITION CORP

 PRESS RELEASE

Waldencast Announces Q2 2025 Results and Provides Q3 2025 Trading Upda...

Waldencast Announces Q2 2025 Results and Provides Q3 2025 Trading Update Transformation efforts drive performance improvements at Obagi Medical with accelerating revenue Contrasted performance for Milk Makeup with Q2 2025 net revenue growth driven by U.S. channel expansion and sell-out acceleration but softer performance in Q3 2025 in international markets Company advances key strategic initiatives, including expansion into medical aesthetics through the Novaestiq acquisition and strengthened balance sheet following the sale of the Obagi Japan trademark and credit facility refinancing Wa...

 PRESS RELEASE

Obagi Medical Shares New Clinical Data on Obagi Hyaluronic Acid Inject...

Obagi Medical Shares New Clinical Data on Obagi Hyaluronic Acid Injectables and Nu-Cil Scalp Serum at the 2025 American Society for Dermatologic Surgery Annual Meeting Obagi® saypha® ChIQ™ data selected as a top 10 cosmetic oral abstract presentation NEW YORK, Nov. 16, 2025 (GLOBE NEWSWIRE) -- Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc (NASDAQ: WALD), today announced new data shared at the recent American Society for Dermatologic Surgery (ASDS) Annual Meeting, which took place November 13–16, 2025, in Chicago, Il...

 PRESS RELEASE

Waldencast plc strengthens balance sheet position with the announcemen...

Waldencast plc strengthens balance sheet position with the announcement of a trademark sale for Japan and refinancing of its credit facilities NEW YORK, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Waldencast plc, (NASDAQ: WALD) (“Waldencast” or the “Company”), a global multi-brand beauty and wellness platform, today announced that it had sold its rights to the “Obagi” trademark in Japan to Rohto Pharmaceutical Co., Ltd. (“Rohto”) for USD $82.5 million. Since 2002, Rohto has licensed the “Obagi” mark for use in the Japanese market to commercialize Rohto’s products. During that time, Rohto has devel...

 PRESS RELEASE

Waldencast plc Provides Information Regarding Upcoming Earnings Releas...

Waldencast plc Provides Information Regarding Upcoming Earnings Release Dates First Half Fiscal 2025 Results and Q3 2025 Financial Results Expected to be Reported on November 24, 2025 LONDON, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Waldencast plc, (NASDAQ: WALD) (“Waldencast”), a global multi-brand beauty and wellness platform, provided additional details for its upcoming earnings release and conference call dates. The Company currently expects to issue Second Quarter Fiscal 2025 Results and Q3 2025 Financial Results on November 24, 2025. The Company does not plan to host a conference call wi...

 PRESS RELEASE

Obagi Medical Launches Nu-Cil® BioStim™ Scalp Serum

Obagi Medical Launches Nu-Cil® BioStim™ Scalp Serum A Next-Generation, Redensifying Scalp Serum Clinically Proven to Promote Fuller, Denser-Looking Hair* NEW YORK, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Obagi Medical (“Obagi”), the fastest growing professional skincare brand in the U.S. in 2024*, proudly unveils its latest innovation rooted in clinical skin science: Nu-Cil® BioStim™ Scalp Serum. Designed to promote a healthier scalp, the foundation of fuller, stronger hair, this advanced leave-in serum is clinically proven to reduce dry, fallen hair by 74% in just three months, helping deliv...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch